Should you buy ADMA Biologics (ADMA)?
Updated
ADMA Biologics screens at a forward price-to-earnings ratio of 8.5x and PEG of 0.18, with a return on equity of 43%, wide moat characteristics, and analyst consensus implying roughly 107% upside; the primary cautions are a free cash flow conversion of only 35% of net income and a confirmed long-term trend breakdown — though improving near-term momentum indicators suggest a recovery setup may be forming.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
At a forward price-to-earnings ratio of 8.5x and a PEG of 0.18, the market is pricing the company's earnings well below its growth rate; analyst consensus implies approximately 107% upside from the current price, reflecting a wide gap between current price and intrinsic value estimates. Valuation breakdown | The forward price-to-earnings ratio expands toward 15x over 12 months as earnings growth is sustained and the market narrows the valuation gap, with the stock price appreciating materially toward analyst targets. | →Stable |
| CounterA low forward multiple in a small-cap biotechnology company can persist indefinitely if the market demands a higher risk premium for clinical, regulatory, or revenue-concentration uncertainty not fully captured in the earnings line. | ||
A return on equity of 43%, margins of 32%, and wide economic moat characteristics place the company in the top tier of its peer group on both return metrics and P/E relative to peers, indicating a franchise that compounds returns at an above-average rate. Peer rank | Return on equity stays above 25% and gross margins remain above 25% over the next four quarters, preserving the peer-relative quality advantage. | →Stable |
| CounterHigh returns on equity in a leveraged structure can be flattered by balance sheet leverage rather than operational excellence; if debt costs rise or revenue moderates, the return profile could compress faster than the margin trend implies. | ||
Free cash flow represents only 35% of net income — a level flagged as a red flag — indicating that reported earnings are significantly overstating the cash actually available to the business, which limits the quality of the earnings stream despite strong headline profitability. Quality breakdown | Free cash flow conversion rises above 80% of net income for 2 consecutive quarters, signaling that the gap between reported earnings and cash generation has narrowed to a sustainable level. | →Stable |
| CounterBelow-100% cash conversion in a growth-stage healthcare company may reflect deliberate investment in working capital and infrastructure to support revenue expansion, which could normalize as growth matures rather than signaling an accounting concern. | ||
At a forward price-to-earnings ratio of 8.5x and a PEG of 0.18, the market is pricing the company's earnings well below its growth rate; analyst consensus implies approximately 107% upside from the current price, reflecting a wide gap between current price and intrinsic value estimates.
→Stable- Expectation
- The forward price-to-earnings ratio expands toward 15x over 12 months as earnings growth is sustained and the market narrows the valuation gap, with the stock price appreciating materially toward analyst targets.
CounterA low forward multiple in a small-cap biotechnology company can persist indefinitely if the market demands a higher risk premium for clinical, regulatory, or revenue-concentration uncertainty not fully captured in the earnings line.
A return on equity of 43%, margins of 32%, and wide economic moat characteristics place the company in the top tier of its peer group on both return metrics and P/E relative to peers, indicating a franchise that compounds returns at an above-average rate.
→Stable- Expectation
- Return on equity stays above 25% and gross margins remain above 25% over the next four quarters, preserving the peer-relative quality advantage.
CounterHigh returns on equity in a leveraged structure can be flattered by balance sheet leverage rather than operational excellence; if debt costs rise or revenue moderates, the return profile could compress faster than the margin trend implies.
Free cash flow represents only 35% of net income — a level flagged as a red flag — indicating that reported earnings are significantly overstating the cash actually available to the business, which limits the quality of the earnings stream despite strong headline profitability.
→Stable- Expectation
- Free cash flow conversion rises above 80% of net income for 2 consecutive quarters, signaling that the gap between reported earnings and cash generation has narrowed to a sustainable level.
CounterBelow-100% cash conversion in a growth-stage healthcare company may reflect deliberate investment in working capital and infrastructure to support revenue expansion, which could normalize as growth matures rather than signaling an accounting concern.
▸ Show 2 more pillars▾ Show fewer
The stock is below its long-term moving average with a confirmed downtrend — the long-term average has crossed below shorter-term levels with a slope of -8.7% over 30 days — but near-term momentum is improving, with MACD turning constructive, RSI at 58, and volume accumulation (rising on-balance volume) all suggesting the initial conditions for a recovery.
→Stable- Expectation
- Price recovers above the 200-day moving average and on-balance volume continues to rise for 8 consecutive weeks, confirming the transition from downtrend to recovery is intact.
CounterA downtrend with a falling long-term moving average slope of -8.7% over 30 days is a persistent signal; near-term improvement in MACD and volume can be false starts, and the confirmed downtrend could resume if the underlying catalyst for recovery does not materialize.
Five news-related risks have been flagged, and the most recent reported quarter missed consensus by approximately 15%, introducing caution about near-term execution and signaling that the current environment warrants waiting for additional clarity before committing capital.
→Stable- Expectation
- The flagged news risks resolve without material adverse impact AND EPS beats consensus by more than 5% for 2 consecutive quarters, confirming the cautionary signals were transient rather than structural.
CounterA single earnings miss preceded by a beat and two in-line quarters does not establish a downward trend; if the miss reflected a timing issue rather than a demand problem, the next quarter's results may demonstrate the concern was overstated.
→ Full pillar scorecard with all 5 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1At a forward price-to-earnings ratio of 8.5x and a PEG of 0.18, the market is pricing the company's earnings well below its growth rate; analyst consensus implies approximately 107% upside from the current price, reflecting a wide gap between current price and intrinsic value estimates.
Trip ifForward P/E rises above 20x, indicating the deep valuation discount has been fully re-rated and the original entry thesis is consumed.
- P2A return on equity of 43%, margins of 32%, and wide economic moat characteristics place the company in the top tier of its peer group on both return metrics and P/E relative to peers, indicating a franchise that compounds returns at an above-average rate.
Trip ifReturn on equity falls below 20% for 2 consecutive quarters, indicating the return advantage versus peers has narrowed materially from the current 43%.
- P3Free cash flow represents only 35% of net income — a level flagged as a red flag — indicating that reported earnings are significantly overstating the cash actually available to the business, which limits the quality of the earnings stream despite strong headline profitability.
Trip ifFree cash flow conversion rises above 80% of net income for 2 consecutive quarters, confirming the earnings-quality concern has resolved.
- P4The stock is below its long-term moving average with a confirmed downtrend — the long-term average has crossed below shorter-term levels with a slope of -8.7% over 30 days — but near-term momentum is improving, with MACD turning constructive, RSI at 58, and volume accumulation (rising on-balance volume) all suggesting the initial conditions for a recovery.
Trip ifRSI falls below 40 and on-balance volume declines for 6 consecutive weeks, confirming the recovery setup has failed and the downtrend has resumed.
- P5Five news-related risks have been flagged, and the most recent reported quarter missed consensus by approximately 15%, introducing caution about near-term execution and signaling that the current environment warrants waiting for additional clarity before committing capital.
Trip ifEPS surprise exceeds 5% for 2 consecutive quarters with no new material news risks flagged, confirming the cautionary setup has fully cleared.
How the engine reached this verdict
TrendMatrix's engine output for ADMA Biologics Inc (ADMA) is STRONG_BUY_WAIT with medium conviction, score 6.5/10 at $8.86. The C-path quality+growth combination cleared its gates — quality 7.8 and growth 8.3 — with 4.81 asymmetric R:R supporting the read.
The engine's suggested entry zone is $8.42, currently 5.2% above entry. Target $15.31, stop $7.74, asymmetric R:R 11.30. The WAIT designation reflects entry-discipline framing — chasing into the current zone compresses asymmetry, which is why the engine separates WAIT from NOW. The engine's sizing output: 1.2% of portfolio at this asymmetry level (high-conviction tier).
On the bull side: High-quality business; Attractive valuation; Strong growth profile. On the bear side: Leverage penalty (D/E 1.1): -0.5; Elevated risk factors; Below 200-MA, MA slope -8.9%/30d (confirmed downtrend). Active engine warnings: News gate: flagged (6 risks, 2 concerns).
BUY_NOW requires asymmetry R:R climbing above the 2.5 conviction threshold (currently 11.30); the verdict flips to HOLD if overall score deteriorates by ~0.7.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates ADMA — 10-dimension breakdown →
Bull case
- ▸High-quality business
- ▸Attractive valuation
- ▸Strong growth profile
Bear case
- ▸Leverage penalty (D/E 1.1): -0.5
- ▸Elevated risk factors
- ▸Below 200-MA, MA slope -8.9%/30d (confirmed downtrend)